[HTML][HTML] Temozolomide and bevacizumab induction before chemoradiotherapy in patients with bulky glioblastoma and/or with severe neurological impairment
I Darmon, MC Morisse, A Coutte, M Blonski… - Journal of …, 2017 - ncbi.nlm.nih.gov
Background. New approaches are needed for patients newly diagnosed with bulky
glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first …
glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first …
Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome
JM Grunda, J Fiveash, CA Palmer, A Cantor… - Clinical cancer …, 2010 - AACR
Purpose: Previous preclinical studies suggested that concurrent capecitabine and radiation
could be an effective new treatment modality for glioblastoma (GBM). In the current study, we …
could be an effective new treatment modality for glioblastoma (GBM). In the current study, we …
RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).
MR Gilbert, M Wang, KD Aldape, R Stupp… - Journal of Clinical …, 2011 - ascopubs.org
2006 Background: Radiotherapy with concomitant and adjuvant TMZ (TMZ/RT→ TMZ) is the
standard of care for newly diagnosed GBM. MGMT methylation status may be an important …
standard of care for newly diagnosed GBM. MGMT methylation status may be an important …
Using Artificial Intelligence and Magnetic Resonance Imaging to Address Limitations in Response Assessment in Glioma
A Krauze - Oncology Insights, 2023 - mediterraneanjournals.com
Gliomas are rapidly progressive, neurologically devastating, nearly uniformly fatal brain
tumors. In WHO grade IV tumors like glioblastoma, the standard of care involves maximal …
tumors. In WHO grade IV tumors like glioblastoma, the standard of care involves maximal …
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo
BM Ellingson, LE Abrey, J Garcia, O Chinot… - Neuro …, 2018 - academic.oup.com
Background In the current study we used contrast-enhanced T1 subtraction maps to test
whether early changes in enhancing tumor volume are prognostic for overall survival (OS) in …
whether early changes in enhancing tumor volume are prognostic for overall survival (OS) in …
In silico modeling predicts drug sensitivity of patient-derived cancer cells
Background Glioblastoma (GBM) is an aggressive disease associated with poor survival. It
is essential to account for the complexity of GBM biology to improve diagnostic and …
is essential to account for the complexity of GBM biology to improve diagnostic and …
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
Purpose This open-label, prospective, multicenter single-arm phase II study combined
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of …
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of …
Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: a multi-institutional collaborative study
Background and purpose A novel molecular recursive partitioning analysis classification has
recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 …
recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 …
On optimal temozolomide scheduling for slowly growing glioblastomas
B Segura-Collar, J Jiménez-Sánchez… - Neuro-Oncology …, 2022 - academic.oup.com
Background Temozolomide (TMZ) is an oral alkylating agent active against gliomas with a
favorable toxicity profile. It is part of the standard of care in the management of glioblastoma …
favorable toxicity profile. It is part of the standard of care in the management of glioblastoma …
Predictive and prognostic markers in human glioblastomas
K Palanichamy, M Erkkinen, A Chakravarti - Current Treatment Options in …, 2006 - Springer
Opinion statement Glioblastomas (GBMs) are among the most aggressive of all known
human tumors. The median survival times remain in the 12-to 15-month range despite …
human tumors. The median survival times remain in the 12-to 15-month range despite …